Research
Hormonal
Weekly subcutaneous Semaglutide 2.4 mg significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with established cardiovascular disease and overweight or obesity, primarily by reducing non-fatal myocardial infarction.
If you have heart disease and are overweight, ask your doctor about Semaglutide 2.4mg. It is a weekly injection proven to lower your risk of heart attack and stroke significantly more than placebo, independent of just weight loss.
StrongSupportsVERY_HIGH confidence
In November 2023, the authors of the SELECT study showed that the primary cardiovascular end-point event (3P-MACE) occurred in 6.5% of patients in the Semaglutide 2.4 mg weekly subcutaneous group and 8.0% in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; p<0.001 for superiority). In particular, with a reduction in non-fatal myocardial infarction (hazard ratio, 0.72; 95% confidence interval, 0.72 to 0.85). These patients had overweight or obesity and established cardiovascular disease (51).
Why this rating
Based on a large, randomized controlled trial (SELECT) with statistically significant results (p<0.001).
Source
La medicina cardiometabolica nell’obesità
-Aggiornamento Dalla Letteratura et al. · il Diabete · 2024
DOI 10.30682/ildia2304d
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Bariatric surgery (RYGB, Sleeve Gastrectomy) significantly reduces long-term cardiovascular mortality and incidence of coronary heart disease, stroke, and myocardial infarction compared to non-surgical management.Good
- Visceral obesity is a critical risk factor for cardiovascular disease, often present in individuals with normal BMI, leading to underestimation of cardiovascular risk in clinical practice.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →